Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Sells $44,884.08 in Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Sravan Kumar Emany sold 11,001 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $4.08, for a total transaction of $44,884.08. Following the completion of the sale, the chief financial officer now directly owns 309,572 shares of the company’s stock, valued at approximately $1,263,053.76. This trade represents a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ironwood Pharmaceuticals Stock Performance

IRWD traded down $0.29 on Wednesday, hitting $3.52. The company had a trading volume of 1,613,600 shares, compared to its average volume of 2,892,309. The stock has a market capitalization of $563.31 million, a price-to-earnings ratio of -127.00 and a beta of 0.47. Ironwood Pharmaceuticals, Inc. has a 12-month low of $3.51 and a 12-month high of $15.70. The stock has a fifty day moving average price of $4.27 and a 200-day moving average price of $5.39.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The firm had revenue of $91.60 million for the quarter, compared to analysts’ expectations of $91.22 million. During the same quarter in the previous year, the firm posted $0.12 EPS. The firm’s revenue for the quarter was down 19.4% compared to the same quarter last year. Analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IRWD has been the subject of several recent analyst reports. StockNews.com downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Craig Hallum decreased their price objective on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Capital One Financial downgraded Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $12.00 to $4.00 in a research report on Thursday, August 8th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. Finally, Wells Fargo & Company reduced their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new position in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at approximately $78,000. Vestcor Inc boosted its holdings in Ironwood Pharmaceuticals by 37.8% in the 3rd quarter. Vestcor Inc now owns 159,466 shares of the biotechnology company’s stock worth $657,000 after buying an additional 43,703 shares during the last quarter. Jane Street Group LLC increased its stake in Ironwood Pharmaceuticals by 102.7% during the 3rd quarter. Jane Street Group LLC now owns 323,638 shares of the biotechnology company’s stock worth $1,333,000 after buying an additional 164,006 shares in the last quarter. Wolverine Trading LLC acquired a new position in shares of Ironwood Pharmaceuticals during the third quarter valued at approximately $51,000. Finally, Weiss Asset Management LP purchased a new position in shares of Ironwood Pharmaceuticals in the third quarter valued at approximately $893,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.